



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Masato Kurokawa et al.

Serial No.: 10/797,606

Art Unit: 1654

Filed : March 11, 2004

Examiner: S. R. Gudibande

Title : WOUND DRESSING FOR ACCELERATING
EPIDERMAL REGENERATION

DECLARATION UNDER RULE 132

Honorable Commissioner of Patents and Trademarks,
Alexandria, Virginia 22313-1450

Sir:

I, Masato Kurokawa, a citizen of Japan and having postal mailing address of Sanyo Chemical Industries, Ltd. 11-1 Ikkyo Nomoto-cho, Higashiyama-ku, Kyoto-shi, Kyoto 605-0995 JAPAN, declare and say that:

In 1988, I was graduated from Hiroshima University and received a Master Degree in the Engineering Faculty;

Since 1988, I have been employed by Sanyo Chemical Industries, Ltd., and I have been engaged in the research of the biomaterial using a genetically engineered cell attachment factor in the Bio & Medical Products Research Department;

I am one of the inventors of the above-identified application and am familiar with the subject matter thereof;

I have read the Official Action mailed and the references cited therein and I am familiar with the subject matter thereof;

I respectfully submit herewith my exact report thereon;

Experiment

Examples 1-7:

Epidermal regeneration accelerating wound dressings (PB1)-(PB7) were prepared in the same manner of the Examples 1-7 in the present invention.

Comparative Example 1:

A sheet (B3) was prepared in the same manner of the Comparative Example 1 in Hahnle. A wound dressing (HB9) was prepared in the same manner of the Example 1 in the present invention except using the above sheet (B3) instead of the sheet (B1).

Evaluation 1 (Cultured skin):

The evaluation for epidermal regeneration effect of the above wound dressings (PB1)-(PB7) and (HB9) was conducted in the same manner of the Evaluation 1 (Cultured skin) in the present invention. The results are shown in the following Table 1.

Droplet absorption rate:

The droplet absorption rate of the above wound dressings (PB1)-(PB7) and (HB9) was measured in the same manner described in Hahnle (column 13, lines 55-60). In Hahnle, the sheet was rated hydrophilic when the absorption time was not more than 5 seconds. The results are shown in the following Table 1.

Table 1

	Wound dressing	Epidermal regeneration	Droplet absorption rate
Example 1	PB1	Excellent	More than 10 min.
Example 2	PB2	Excellent	More than 10 min.
Example 3	PB3	Excellent	More than 10 min.
Example 4	PB4	Excellent	More than 10 min.
Example 5	PB5	Excellent	More than 10 min.
Example 6	PB6	Excellent	More than 10 min.
Example 7	PB7	Excellent	More than 10 min.
Comp.Example 1	HB9	Poor	Not more than 1 sec.


Results

From the above results, the epidermal regeneration accelerating wound dressings of the present invention were hydrophobic, and the wound dressing of the combination of references (Ferrari and Hahnle) was hydrophilic.

The wound dressings of the present invention showed overall epidermal regeneration, though the wound dressing of the combination of references showed no epidermal regeneration. Namely, the above results show that the wound dressings of the present invention have much more excellent effects in the epidermal regeneration than that of the combination of references.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signed this day of , 2006

 27th June, 2006

Masato Kurokawa